CVM · Cel Sci Corp · Insider Trading
Substantial doubt about the company's ability to continue as a going concern.
“Due to recurring losses from operations and future liquidity needs, there is substantial doubt about the Company's ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.”View the 10-Q filed Aug 14, 2026
Trades by corporate insiders — officers, directors and holders of more than 10% of the shares — disclosed to the SEC on Forms 4 and 5. Form 3 supplies initial ownership rather than a trade; Form 4 must be filed within two business days of the trade.
Insider Sentiment Score
Peer-relative 0–100 rank of how aggressively insiders accumulated over the trailing 90 days. See the full ranking.
| Date | Insider | Role | Type | Security | Shares |
|---|---|---|---|---|---|
| 2026-09-30 | KERSTEN GEERT R |
Director, Chief Executive Officer |
Award↑
|
Common Stock
|
2,621 |
| 2026-09-30 | PRICHEP PATRICIA B |
Chief Financial Officer |
Award↑
|
Common Stock
|
2,082 |
| 2026-09-30 | TALOR EYAL |
Chief Scientific Officer |
Award↑
|
Common Stock
|
1,165 |
| 2026-08-25 | KERSTEN GEERT R |
Director, Chief Executive Officer |
Buy↑
Filing footnotes — Common Stock (Direct)
On August 25, 2026, Mr. Kersten purchased 100,000 shares of restricted stock directly from the Company at the closing price on August 24, 2026, the most recent closing price available. |
Common Stock
|
100,000 |
| 2026-08-14 | PRICHEP PATRICIA B |
Chief Financial Officer |
Award↑
Filing footnotes — Options (Direct)
The stock options vest in three (3) equal annual installments commencing one year after the grant date. |
Options
|
225,000 |
| 2026-08-14 | Watson Robert Eugene |
Director |
Award↑
Filing footnotes — Options (Direct)
The stock options vest in three (3) equal annual installments commencing one year after the grant date. |
Options
|
110,000 |
| 2026-08-14 | KERSTEN GEERT R |
Director, Chief Executive Officer |
Award↑
Filing footnotes — Options (Direct)
The stock options vest in three (3) equal annual installments commencing one year after the grant date. |
Options
|
300,000 |
| 2026-08-14 | TALOR EYAL |
Chief Scientific Officer |
Award↑
Filing footnotes — Options (Direct)
The stock options vest in three (3) equal annual installments commencing one year after the grant date. |
Options
|
250,000 |
| 2026-08-14 | CIPRIANO JOHN |
Senior Vice President |
Award↑
Filing footnotes — Options (Direct)
The stock options vest in three (3) equal annual installments commencing one year after the grant date. |
Options
|
80,000 |
| 2026-08-14 | BAILLAVOINE BRUNO JEAN-MARIE |
Director |
Award↑
Filing footnotes — Options (Direct)
The stock options vest in three (3) equal annual installments commencing one year after the grant date. |
Options
|
110,000 |
| 2026-06-30 | TALOR EYAL |
Chief Scientific Officer |
Award↑
|
Common Stock
|
2,307 |
| 2026-06-30 | PRICHEP PATRICIA B |
Chief Financial Officer |
Award↑
|
Common Stock
|
4,125 |
| 2026-06-30 | KERSTEN GEERT R |
Director, Chief Executive Officer |
Award↑
|
Common Stock
|
5,192 |
| 2026-05-14 | KERSTEN GEERT R |
Director, Chief Executive Officer |
Buy↑
Filing footnotes — Common Stock (Indirect)
On May 14, 2026, the de Clara Trust, of which Mr. Kersten is a trustee, purchased 300,000 shares of restricted stock directly from the Company at the closing price on May 13, 2026, the most recent closing price available. |
Common Stock
(I)
|
300,000 |
| 2026-05-13 | KERSTEN GEERT R |
Director, Chief Executive Officer |
Buy↑
Filing footnotes — Common Stock (Direct)
On May 13, 2026, Mr. Kersten purchased 100,000 shares of restricted stock directly from the Company at the closing price on May 12, 2026, the most recent closing price available. |
Common Stock
|
100,000 |
| 2026-03-31 | TALOR EYAL |
Chief Scientific Officer |
Award↑
|
Common Stock
|
747 |
| 2026-03-31 | PRICHEP PATRICIA B |
Chief Financial Officer |
Award↑
|
Common Stock
|
1,336 |
| 2026-03-31 | KERSTEN GEERT R |
Director, Chief Executive Officer |
Award↑
|
Common Stock
|
1,682 |
| 2026-01-22 | KERSTEN GEERT R |
Director, Chief Executive Officer |
Buy↑
Filing footnotes — Common Stock (Direct)
On January 22, 2026, Mr. Kersten purchased 38,023 shares of restricted stock directly from the Company at the closing price on January 21, 2026, the most recent closing price available. |
Common Stock
|
38,023 |
| 2025-12-31 | PRICHEP PATRICIA B |
Chief Financial Officer |
Award↑
|
Common Stock
|
815 |
| 2025-12-31 | KERSTEN GEERT R |
Director, Chief Executive Officer |
Award↑
|
Common Stock
|
998 |
| 2025-12-31 | TALOR EYAL |
Chief Scientific Officer |
Award↑
|
Common Stock
|
456 |
| 2025-12-04 | KERSTEN GEERT R |
Director, Chief Executive Officer |
Buy↑
Filing footnotes — Common Stock (Direct)
On December 4, 2025, Mr. Kersten purchased 8,389 shares of restricted stock directly from the Company at the closing price on December 3, 2025, the most recent closing price available. |
Common Stock
|
8,389 |
| 2025-09-30 | TALOR EYAL |
Chief Scientific Officer |
Award↑
|
Common Stock
|
260 |
| 2025-09-30 | KERSTEN GEERT R |
Director, Chief Executive Officer |
Award↑
|
Common Stock
|
570 |
| 2025-09-30 | PRICHEP PATRICIA B |
Chief Financial Officer |
Award↑
|
Common Stock
|
466 |
| 2025-07-28 | KERSTEN GEERT R |
Director, Chief Executive Officer |
Award↑
Filing footnotes — Options (Direct)
The stock options vest in three (3) equal annual installments commencing one year after the grant date. |
Options
|
25,000 |
| 2025-07-28 | BAILLAVOINE BRUNO JEAN-MARIE |
Director |
Award↑
Filing footnotes — Options (Direct)
The stock options vest in three (3) equal annual installments commencing one year after the grant date. |
Options
|
4,000 |
| 2025-07-28 | Watson Robert Eugene |
Director |
Award↑
Filing footnotes — Options (Direct)
The stock options vest in three (3) equal annual installments commencing one year after the grant date. |
Options
|
4,000 |
| 2025-07-28 | TALOR EYAL |
Chief Scientific Officer |
Award↑
Filing footnotes — Options (Direct)
The stock options vest in three (3) equal annual installments commencing one year after the grant date. |
Options
|
15,000 |
| 2025-07-28 | CIPRIANO JOHN |
Senior Vice President |
Award↑
Filing footnotes — Options (Direct)
The stock options vest in three (3) equal annual installments commencing one year after the grant date. |
Options
|
7,500 |
| 2025-07-28 | PRICHEP PATRICIA B |
Chief Financial Officer |
Award↑
Filing footnotes — Options (Direct)
The stock options vest in three (3) equal annual installments commencing one year after the grant date. |
Options
|
12,000 |
| 2025-07-25 | KERSTEN GEERT R |
Director, Chief Executive Officer |
Buy↑
Filing footnotes — Common Stock (Direct)
On July 25, 2025, Mr. Kersten purchased 29,197 shares of restricted stock directly from the Company at the closing price on July 24, 2025, the most recent closing price available. |
Common Stock
|
29,197 |
| 2025-07-25 | Watson Robert Eugene |
Director |
Buy↑
Filing footnotes — Common Stock (Direct)
On July 25, 2025, Mr. Watson purchased 2,919 shares of restricted stock directly from the Company at the closing price on July 24, 2025, the most recent closing price available. |
Common Stock
|
2,919 |
| 2025-06-30 | TALOR EYAL |
Chief Scientific Officer |
Award↑
|
Common Stock
|
1,048 |
| 2025-06-30 | KERSTEN GEERT R |
Director, Chief Executive Officer |
Award↑
|
Common Stock
|
2,292 |
| 2025-06-30 | PRICHEP PATRICIA B |
Chief Financial Officer |
Award↑
|
Common Stock
|
1,873 |
| 2025-03-31 | PRICHEP PATRICIA B |
Chief Financial Officer |
Award↑
|
Common Stock
|
15,432 |
| 2025-03-31 | KERSTEN GEERT R |
Director, Chief Executive Officer |
Award↑
|
Common Stock
|
22,786 |
| 2025-03-31 | TALOR EYAL |
Chief Scientific Officer |
Award↑
|
Common Stock
|
10,416 |
| 2024-12-31 | TALOR EYAL |
Chief Scientific Officer |
Award↑
|
Common Stock
|
6,001 |
| 2024-12-31 | PRICHEP PATRICIA B |
Chief Financial Officer |
Award↑
|
Common Stock
|
10,727 |
| 2024-12-31 | KERSTEN GEERT R |
Director, Chief Executive Officer |
Award↑
|
Common Stock
|
12,940 |
| 2024-09-30 | KERSTEN GEERT R |
Director, Chief Executive Officer |
Award↑
|
Common Stock
|
4,882 |
| 2024-09-30 | TALOR EYAL |
Chief Scientific Officer |
Award↑
|
Common Stock
|
2,264 |
| 2024-09-30 | PRICHEP PATRICIA B |
Chief Financial Officer |
Award↑
|
Common Stock
|
4,047 |
| 2024-06-28 | TALOR EYAL |
Chief Scientific Officer |
Award↑
|
Common Stock
|
2,068 |
| 2024-06-28 | PRICHEP PATRICIA B |
Chief Financial Officer |
Award↑
|
Common Stock
|
3,698 |
| 2024-06-28 | KERSTEN GEERT R |
Director, Chief Executive Officer |
Award↑
|
Common Stock
|
4,461 |
| 2024-05-08 | Watson Robert Eugene |
Director |
Buy↑
Filing footnotes — Common Stock (Direct)
On May 8, 2024, Mr. Watson purchased 20,000 shares of restricted stock directly from the Company at the closing price on May 8, 2024, the most recent closing price available. |
Common Stock
|
20,000 |